Telehealth Intake: What Happens Between Sign-Up and First Dose

A telehealth GLP-1 program usually starts the same way: a short online quiz asking about your health history, current conditions, and medications. It feels like the whole process, since it's the only part you can see. But the quiz is the beginning of an intake pipeline, not the end of one, and knowing what happens after you submit it changes how you should read the marketing around any of these programs.

The questionnaire is a form, not a decision

The intake form collects the same categories of information a doctor's office intake form asks for: medical history, current diagnoses, medications you take, allergies, and sometimes recent labs or a photo for identity verification. None of that data approves or denies you anything by itself. It is a structured way to hand a licensed provider the information they need to make a clinical judgment, reached from the intake record rather than from an in-person exam.

This distinction matters because a completed quiz can feel like a green light. It isn't one. The FDA's prescribing information for semaglutide states plainly that it is a prescription medicine, meaning a licensed prescriber has to authorize its use before it can be dispensed. A telehealth platform doesn't get to skip that step just because the intake happens online; it still routes through a person with a license, reviewing your specific answers against the drug's approved use and any contraindications.

Who reviews the answers, and what they're looking for

After you submit the quiz, a licensed provider reviews it. In the MEDGm program, that review happens before any prescription is written, and it's the provider, not the quiz, who decides whether treatment is clinically appropriate for you. If it is, the program says a provider may prescribe compounded semaglutide, as an injection or as an oral form, or compounded tirzepatide as an injection.

It's worth being precise about what "compounded" means here. A compounded medication is prepared by a pharmacy rather than manufactured and approved as a finished drug product by the FDA. The FDA's own wording is blunt about it: compounded drugs are not approved by FDA. The agency has also spelled out when compounding pharmacies are and are not permitted to prepare these products, closing the enforcement-discretion exceptions that applied while semaglutide and tirzepatide were in national shortage. None of that makes a provider's review less real. It does mean the product you receive sits in a different regulatory lane than an FDA-approved drug, which is worth understanding before you sign up, not after.

From checkout to the first shipment

Once a provider approves treatment, the practical steps are straightforward: your plan and dosing are set, the pharmacy prepares your medication, and it ships to your door. From there, ongoing care in this model runs on scheduled follow-ups rather than walk-in visits. Some programs, including the MEDGm program page, structure this as a check-in every 12 weeks, where dose and plan can be adjusted based on how you're doing, alongside refills and continued shipping. That cadence is the program's mechanism for catching problems and adjusting course, and it is worth knowing before signing up, because it sets how long a question waits for an answer.

If you want the same ground covered at more length, the guide collection on what happens during telehealth intake walks through the sequence step by step.

Why eligibility isn't the same everywhere

A flat subscription price and a simple sign-up flow can make a program feel uniform across the country. It isn't. Compounding pharmacies and the products they prepare are governed by state pharmacy law as well as federal rules, and a program that's live in most states can still be closed in specific ones. The MEDGm program is not available in Louisiana, where compounded GLP-1 medication for weight loss is prohibited, and it excludes patients under 19 in Nebraska. Those aren't edge cases buried in fine print; they're the kind of restriction that determines whether the sign-up flow will even let you finish, so it's worth checking against where you live before you start the quiz.

The same principle shows up at a federal level in a different form. CMS's GLP-1 bridge program for Medicare beneficiaries sets a flat $50 monthly copay through Part D plans, but it still tells beneficiaries to talk with their doctor about whether the medication is right for them. A set price and a clinical decision are two separate pieces of any GLP-1 access program, whether it's run through Medicare or through a telehealth platform. The price tells you what you'll pay. It doesn't tell you whether you'll be approved, and it shouldn't.

What to expect if you're considering one

This is not an argument for or against telehealth GLP-1 programs. It is a description of the actual steps: fill out a detailed questionnaire, wait for a licensed provider to review it against your specific health history, get a decision that may or may not be a prescription, and if it is, expect scheduled follow-ups rather than a one-time transaction. The MEDGm program page lays out its own quiz-to-shipping flow and current pricing if you want to see the specifics for that program. Whichever platform you're weighing, the questions worth asking before you start are the same: who reviews your answers, how often you'll be checked in on afterward, and whether the program operates where you live.

Sources

• Wegovy (semaglutide) FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf, revised 08/2025, weight reduction in adults and patients aged 12 and older with obesity and in adults with overweight plus at least one weight-related condition, with separate cardiovascular and MASH indications, prescription-only injectable used alongside a reduced-calorie diet and increased physical activity, chronic ongoing use, endpoint: the label and its Medication Guide describe the product as an injectable prescription medicine, so dispensing requires authorization by a licensed prescriber, limitation: the label does not describe telehealth intake workflows, which vary by platform and state.
• FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize". https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize, 503A and 503B compounding pharmacies, compounded semaglutide and tirzepatide, enforcement-discretion periods that ended between February and May 2025, endpoint: states that compounded drugs are not approved by FDA, and gives the regulatory basis for why compounded GLP-1 products are a distinct category from FDA-approved drugs, limitation: sets a uniform federal framework, not a state-by-state or program-specific access list.
• CMS, Medicare GLP-1 Bridge Program announcement. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries, Medicare Part D enrollees, a $50 monthly copay through existing Part D plans, program runs July 2026 through December 2027, endpoint: a federal example where a flat price and a clinician's decision remain separate steps, limitation: covers a different eligibility population and intake path than a direct-to-consumer telehealth quiz.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.